Skip to content
Search

Latest Stories

Foreign funds turn off supply, leave Indian markets gasping

Indian stocks were the third-worst performers among leading emerging markets in September as foreign portfolio investors pulled money out of the country at the fastest pace since November last year amid a slide in the rupee.

Market participants said foreigners shifted money from the expensively valued domestic shares to cheaper destinations on worries that corporate earnings growth will take time to revive. 


Repeated comments by the US Federal Reserve on normalisation of monetary policy have also affected sentiment in emerging markets, such as India, with high foreign holdings.

The Sensex fell 1.4% during the month while Nifty lost 1.3%. If not for the strong inflows of over Rs 20,000 crore by domestic institutions — mutual funds and insurers — during the month, losses would have been bigger. Foreign portfolio investors pulled out close to Rs 13,400 crore in September.

This includes Friday's provisional figure of Rs 1,547 crore worth of selling by foreign investors and Rs 2,065 crore of buying by domestic institutional investors. 

Taiwan and South Africa, which fell 2.4% and 2.7% respectively in September, were worse off than India. Brazil, Thailand, Philippines and South Korea advanced 1.3%-3.9%. The near-term market direction will depend on foreign fund flows. 

"FII (foreign institutional investor) outflows will continue. Generally, they are pulling out money from EMs (emerging markets) in response to normalisation of policy by the Fed and in expectation that ECB (European Central Bank) could also look at tapering when it meets in October," said Abhay Laijawala, head of research at Deutsche Equities India.

Foreign investors have sold Indian shares for the second month in a row in September. 

They dumped equities worth Rs 12,600 crore in August. In the past, foreign fund selloffs of this magnitude have resulted in steep falls in the market.

But this time around, domestic institutions have cushioned the fall, armed as they are with funds pumped in by retail investors who are shifting from fixed deposits, real estate and gold to equities. In August, domestic institutions bought stocks worth Rs 16,200 crore. 

Since January, domestic institutional investors have pumped in Rs 63,215 crore. In the current calendar year, foreign investors remain net buyers of shares worth about Rs 32,300 crore, even after their selling spree in August and September.

India remains overweight for overseas investors, but they would rather wait for some positive triggers before allocating incremental money, experts said. 

"From a long-term perspective, investors are positive on reforms and the country's prospects. However, in the near term, they believe markets can be volatile as the economy rebalances following rapid rollout of transformational reforms," said Laijawala. Share valuations are offering no comfort to investors either, said analysts. 

The Sensex is trading at roughly 20 times earnings estimates for the current financial year compared with 14 times for the MSCI Emerging Market Index. "After the strong 20% rally year to date, valuations are a tad demanding.

Also, earnings estimates continue to be revised down. At the start of the fiscal year, the street was expecting 20% earnings growth (for FY18), but now the expectation stands reduced to 14%," said Bharat Iyer, head of India equity research at JPMorgan. 

Iyer cautioned the earnings growth number could be lower still. So far in 2017, Indian indices have been among the best performers in emerging markets. The Nifty is up 19.6% since January while the Sensex is up 17.5%. "For foreign investors to put incremental money to work, there should either be a pullback in the markets or earnings should recover," said Iyer.

More For You

modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less